Topic:

M&A

Latest Headlines

Latest Headlines

Alere shakes up boardroom, embarks on strategic review

Still finding its footing after irked investors mounted a proxy challenge last year, Alere is shuffling its top ranks and setting out on a review of its operations, a move that could spell more divestitures.

Up, up, up: After Allergan offer, would-be buyer Ackman reaps $1.2B in gains

Valeant and partner Bill Ackman may not yet have bagged acquisition target Allergan, but shares have leapt since the takeover team went public with its plans in mid-April, helping push gains for Ackman's hedge fund, Pershing Square Capital Management, to $1.2 billion.

AstraZeneca's tarnished R&D image haunts its fight against Pfizer

Up to now about the only reason any serious analyst could justify Pfizer's interest in AstraZeneca's pipeline centered on its early-stage work in immuno-oncology. But the U.K.'s Sky News city editor says that the company will be highlighting all of its "hidden gems" in long-term development as a solid reason why investors should give Pfizer's $106 billion buyout offer a pass.

Teva could jump into pharma's deal frenzy, CEO says

A few months ago, Teva CFO Eyal Desheh told the J.P. Morgan Healthcare Conference that armed with a new incoming CEO and a reasonable debt level, the Israeli company was ready to make some deals. So with an M&A wave taking the pharma industry by storm, where is Teva in the melee?

Reports: Bayer closing in on deal for Merck OTC unit with Reckitt out of the way

With Reckitt Beckiser out of the race for Merck's consumer health unit, Bayer is in exclusive talks with the New Jersey company, reports say, and it could have a $14 billion deal wrapped up in the next few days.

Pfizer's approach may turn hostile after AZ rejects second offer

Pfizer upped its offer for AstraZeneca today from $100 billion to $106 billion, and AstraZeneca dutifully rejected it, but experience in the world of pharma takeovers tells us this is unlikely to be the end of the drama.

AstraZeneca bars the door, but Pfizer presses on with $106B buyout bid

AstraZeneca's board has rejected Pfizer's sweetened $106 billion bid for the company, dismissing the mix of cash and stock behind the £ 50 ($84.47) offer as inadequate and ignoring a pledge from Pfizer to push ahead with a major new R&D complex in Cambridge while retaining a large contingent of researchers in the U.K. for at least 5 years.

Wright revives prospects of bone graft with FDA resubmission

Wright Medical Group has just submitted a PMA amendment for its Augment bone graft, CEO Robert Palmisano told investors, in what amounts to compromise with the FDA.

Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout

Even as reports of a prospective takeover bid from Allergan circulate, Shire CEO Flemming Ornskov shows no sign of slowing down on the company's deal spree. The biotech is buying Australia's Fibrotech for $75 million upfront and a string of undisclosed milestones, bringing in a lead drug for fibrosis.

Can anything prevent Pfizer's megamerger with AstraZeneca?

The  Financial Time s got hold of a couple of AstraZeneca's biggest investors this week and found that they were discreetly wide open to a Pfizer takeover--provided the U.S. pharma giant agreed to make an offer they couldn't refuse.